LAS VEGAS, NV--(Marketwired - Apr 23, 2015) - Alkame Holdings, Inc. (
Alkame Water has signed a distribution agreement with Florida-based OnPoint Distribution, a leading distribution (DSD) and brand Management Company focused on representing and partnering with natural, organic and specialty food product brands that target health-conscious consumers.
Alkame Holdings, Inc. CEO, Robert Eakle states, "We are so pleased to have signed a distribution agreement with OnPoint Distribution to assist us in penetrating the Florida marketplace. The team at OnPoint Distribution provides not only distribution, but also offers a unique combination of product knowledge and options for in-store services including live demonstrations and tastings. We expect OnPoint Distribution to immediately impact our sales in the Florida market. This agreement makes it easier for us to quickly generate brand awareness and sales."
About Alkame Holdings, Inc. (ALKM)
Alkame Holdings, Inc. is a publicly traded health and technology holding company with a focus on patentable, innovative, and eco-friendly consumer products. The Company's wholly-owned subsidiary, Alkame Water, Inc., markets and distributes micro-clustered, alkaline, antioxidant and oxygenated bottled water utilizing an exclusive patented formula and technology. Alkame uses this patented technology to create water with several unique properties which allow the body to absorb and utilize it more efficiently and help to achieve an optimal pH balance. This patented technology also increases the available oxygen content and absorbability which equates to more fuel for improved metabolic efficiency, boosted immune system, and improved cardio respiratory function.
For more information visit: www.alkameholdingsinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.